Volume | 1 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Arrowhead Pharmaceuticals Inc | ARWR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
28.70 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 1 | - | 20.67 - 42.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:01:43 | 1 | $ 28.77 | USD |
Arrowhead Pharmaceuticals (ARWR) Options Flow Summary
Arrowhead Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.56B | 123.90M | - | 240.74M | -205.28M | -1.66 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Arrowhead Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARWR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.97 | 29.93 | 27.18 | 27.97 | 716,279 | -0.27 | -0.93% |
1 Month | 34.50 | 36.72 | 27.00 | 30.55 | 1,407,232 | -5.80 | -16.81% |
3 Months | 32.63 | 39.83 | 27.00 | 32.78 | 1,591,116 | -3.93 | -12.04% |
6 Months | 26.33 | 39.83 | 20.67 | 29.72 | 1,435,864 | 2.37 | 9.00% |
1 Year | 24.25 | 42.48 | 20.67 | 30.85 | 1,195,484 | 4.45 | 18.35% |
3 Years | 62.57 | 93.66 | 20.67 | 40.75 | 934,123 | -33.87 | -54.13% |
5 Years | 17.78 | 93.66 | 17.25 | 42.14 | 1,155,159 | 10.92 | 61.42% |
Arrowhead Pharmaceuticals Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |